We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
A highly selective, potent antagonist for the opioid δ-receptor. It exhibits partial agonist in vitro activity at δ receptors at high concentrations.
CAT No: R1076
CAS No: 89352-67-0
Synonyms/Alias: ICI 174,864;92535-15-4;N,N-diallyl-Tyr-Aib-Aib-Phe-Leu;89352-67-0;Ici 174865;Ici 174,865;N,N-Diallyl-tyr-aib-aib-phe-leu-OH;ICI-174865;ICI-174,865;CHEMBL47545;N,N-Diallyl-tyrosyl-aminoisobutyryl-aminoisobutyryl-phenylalanyl-leucine;L-Leucine, N-(N-(N-(N-(N,N-di-2-propenyl-L-tyrosyl)-2-methylalanyl)-2-methylalanyl)-L-phenylalanyl)-;N-(N-(N-(N-(N,N-di-2-Propenyl-L-tyrosyl)-2-methylalanyl)-2-methylalanyl)-L-phenylalanyl)-L-leucine;(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-2-methylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid;(2S,5S,14S)-15-allyl-5-benzyl-14-(4-hydroxybenzyl)-2-isobutyl-8,8,11,11-tetramethyl-4,7,10,13-tetraoxo-3,6,9,12,15-pentaazaoctadec-17-en-1-oic acid;NIH10893;DTXSID10919119;BDBM50006946;AKOS024458657;DA-54236;PD071343;CS-0134163;L-Leucine,N,N-di-2-propen-1-yl-L-tyrosyl-2-methylalanyl-L-phenylalanyl-;L-Leucine, N,N-di-2-propen-1-yl-L-tyrosyl-2-methylalanyl-2-methylalanyl-L-phenylalanyl-;2-[2-(2-{2-[2-Diallylamino-3-(4-hydroxy-phenyl)-propionylamino]-2-methyl-propionylamino}-2-methyl-propionylamino)-3-phenyl-propionylamino]-4-methyl-pentanoic acid;N-{2-Benzyl-1,4,7,10-tetrahydroxy-11-[(4-hydroxyphenyl)methyl]-5,5,8,8-tetramethyl-12-(prop-2-en-1-yl)-3,6,9,12-tetraazapentadeca-3,6,9,14-tetraen-1-ylidene}leucine;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C38H53N5O7 |
M.W/Mr. | 691.9 |
Sequence | One Letter Code:YXXFL Three Letter Code:N(allyl2)Tyr-Aib-Aib-Phe-Leu-OH |
Labeling Target | Opioid Receptor |
Appearance | White lyophilised solid |
Purity | >98% |
Activity | Antagonist |
Long-term Storage Conditions | Soluble in DMSO |
InChI | InChI=1S/C38H53N5O7/c1-9-20-43(21-10-2)31(24-27-16-18-28(44)19-17-27)33(46)41-38(7,8)36(50)42-37(5,6)35(49)40-29(23-26-14-12-11-13-15-26)32(45)39-30(34(47)48)22-25(3)4/h9-19,25,29-31,44H,1-2,20-24H2,3-8H3,(H,39,45)(H,40,49)(H,41,46)(H,42,50)(H,47,48)/t29-,30-,31-/m0/s1 |
InChI Key | XUWLAGNFLUARAN-CHQNGUEUSA-N |
BoilingPoint | 892.7ºC at 760 mmHg |
Melting Point | N/A |
1. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
2. The spatiotemporal control of signalling and trafficking of the GLP-1R
4. High fat diet and GLP-1 drugs induce pancreatic injury in mice
5. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com